CHRISTIE BALLANTYNE to Factor Xa Inhibitors
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Factor Xa Inhibitors.
Connection Strength
0.169
-
Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System. Cardiovasc Drugs Ther. 2021 06; 35(3):533-538.
Score: 0.169
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.